Vijay Kumar

Prof. Vijay Kumar

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in World Journal of Gastroenterology
Verified
Journal Article
Open access
TCTenzin Choedon
Tenzin Choedon
GMGaneshan Mathan
Ganeshan Mathan
SASoneera Arya
Soneera Arya
VKVijay L Kumar
Vijay L Kumar
VKVijay Kumar
Vijay Kumar
Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma

1 January 2016 in Journal of Oral Biology and Craniofacial Research
Verified
Journal Article
Closed access
MSMahendra Pratap Singh
Mahendra Pratap Singh
VKVijay Kumar
Vijay Kumar
AAAkash Agarwal
Akash Agarwal
RKRajendra Kumar
Rajendra Kumar
MBM.L.B. Bhatt
M.L.B. Bhatt
SMSanjeev Misra
Sanjeev Misra

11 December 2006 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
AMAtish Mukherji
Atish Mukherji
VJVaibhao C. Janbandhu
Vaibhao C. Janbandhu
VKVijay Kumar
Vijay Kumar
The HBx (X protein of hepatitis B virus) is a promiscuous transactivator implicated to play a key role in hepatocellular carcinoma. However, HBx-regulated molecular events leading to deregulation of cell cycle or establishment of a permissive environment for hepatocarcinogenesis are not fully understood. Our cell culture-based studies suggested that HBx had a profound effect on cell cycle progression even in the absence of serum. HBx presence led to an early and sustained level of cyclin–cdk2 complex during the cell cycle combined with increased protein kinase activity of cdk2 heralding an early proliferative signal. The increased cdk2 activity also led to an early proteasomal degradation of p27Kip1 that could be reversed by HBx-specific RNA interference and blocked by a chemical inhibitor of cdk2 or the T187A mutant of p27. Further, our co-immunoprecipitation and in vitro binding studies with recombinant proteins suggested a direct interaction between HBx and the cyclin E/A–cdk2 complex. Interference with different signalling cascades known to be activated by HBx suggested a constitutive requirement of Src kinases for the association of HBx with these complexes. Notably, the HBx mutant that did not interact with cyclin E/A failed to destabilize p27Kip1 or deregulate the cell cycle. Thus HBx appears to deregulate the cell cycle by interacting with the key cell cycle regulators independent of its well-established role in transactivation.

1 August 2017 in Virus Research
Verified
Journal Article
Closed access
NKNeetu Rohit Kapoor
Neetu Rohit Kapoor
RCRadhika Chadha
Radhika Chadha
SKSaravanan Kumar
Saravanan Kumar
TCTenzin Choedon
Tenzin Choedon
VRVanga Siva Reddy
Vanga Siva Reddy
VKVijay Kumar
Vijay Kumar

1 March 2015 in Gene
Verified
Journal Article
Closed access
NNNagisa Nosrati
Nagisa Nosrati
NKNeetu Rohit Kapoor
Neetu Rohit Kapoor
VKVijay Kumar
Vijay Kumar

16 March 2021 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
DCD Chakrabarti
D Chakrabarti
SRS Rajan
S Rajan
NAN Akhtar
N Akhtar
SQS Qayoom
S Qayoom
SGS Gupta
S Gupta
RGR Gupta
R Gupta
The trial hypothesis was that, in a resource-constrained situation, short-course radiotherapy would improve treatment compliance compared with conventional chemoradiotherapy for locally advanced rectal cancer, without compromising oncological outcomes. In this open-label RCT, patients with cT3, cT4 or node-positive non-metastatic rectal cancer were allocated randomly to 5 × 5 Gy radiotherapy and two cycles of XELOX (arm A) or chemoradiotherapy with concurrent capecitabine (arm B), followed by total mesorectal excision in both arms. All patients received a further six cycles of adjuvant chemotherapy with the XELOX regimen. The primary endpoint was treatment compliance, defined as the ability to complete planned treatment, including neoadjuvant radiochemotherapy, surgery, and adjuvant chemotherapy to a dose of six cycles. Of 162 allocated patients, 140 were eligible for analysis: 69 in arm A and 71 in arm B. Compliance with planned treatment (primary endpoint) was greater in arm A (63 versus 41 per cent; P = 0.005). The incidence of acute toxicities of neoadjuvant therapy was similar (haematological: 28 versus 32 per cent, P = 0.533; gastrointestinal: 14 versus 21 per cent, P = 0.305; grade III–IV: 2 versus 4 per cent, P = 1.000). Delays in radiotherapy were less common in arm A (9 versus 45 per cent; P < 0.001), and overall times for completion of neoadjuvant treatment were shorter (P < 0.001). The rates of R0 resection (87 versus 90 per cent; P = 0.554), sphincter preservation (32 versus 35 per cent; P = 0.708), pathological complete response (12 versus 10 per cent; P = 0.740), and overall tumour downstaging (75 versus 75 per cent; P = 0.920) were similar. Downstaging of the primary tumour (ypT) was more common in arm A (P = 0.044). There was no difference in postoperative complications between trial arms (P = 0.838). Reduced treatment delays and a higher rate of compliance were observed with treatment for short-course radiotherapy with consolidation chemotherapy, with no difference in early oncological surgical outcomes. In time- and resource-constrained rectal cancer units in developing countries, short-course radiotherapy should be the standard of care.